Corrigendum to "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease". (7th April 2020)

• Record Type: Journal Article
• Authors: Lewis, John E.; Atlas, Steven E.; Higuera, Oscar L.; Fiallo, Andrea; Rasul, Ammar; Farooqi, Ashar; Kromo, Olga; Lantigua, Laura A.; Tiozzo, Eduard; Woolger, Judi M.; Goldberg, Sharon; Mendez, Armando; Rodriguez, Allan E.; Konefal, Janet
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2020(2020)
• Publication Date: 2020-04-07
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2020/9575878
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions ( n = 12 RBAC and n = 11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (−3.1%; SD = 19.9; F [1, 19] = 5.1, p = 0.03 ) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F [1, 19] = 5.9, p = 0.02 ) and percent eosinophils (30.6%; SD = 30.5; F [1, 19] = 12.3, p < 0.01 ) increased in the RBAC group. IFN- γ (156%; SD = 131.8; F [1, 19] = 4.2, p = 0.06 ) and IL-18 (29.1%; SD = 64; F [1, 19] = 5.3, p = 0.03 ) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ -glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD. This trial is registered with NCT02568787 .